(10% Negative) SOLIGENIX, INC. (SNGX) Announces Delay in halt Trials for futility Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s)